Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. appears in FDA public data with 2 recalls, 0 510(k) clearances, 16 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0017-2019, Class III) was initiated on September 17, 2018.
Summary
- Total Recalls
- 2
- 510(k) Clearances
- 0
- Inspections
- 16
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0017-2019 | Class III | treatNOW ABILIFY (aripiprazole) and ABILIFY MAINTENA (aripiprazole) 400MG for extended release injec | September 17, 2018 |
| D-0018-2019 | Class III | treatNOW ABILIFY (aripiprazole) / ABILIFY MAINTENA 400-mg (aripiprazole) for extended release inject | September 17, 2018 |